REGENERON PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Income Taxes
REGENERON PHARMACEUTICALS, INC. (REGN) reported Increase (Decrease) in Deferred Income Taxes of $290.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for the quarter ending 2026-06-30 was $194.40M, a 43.79% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for the quarter ending 2026-03-31 was $96.00M, a 30.98% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for the quarter ending 2025-12-31 was $232.50M, a 17.02% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for the quarter ending 2025-09-30 was $278.60M, a 65.24% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for fiscal 2025 was $785.40M, a 3.71% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for fiscal 2024 was $757.30M, a 9.61% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for fiscal 2023 was $837.80M, a 12.25% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred income taxes for fiscal 2022 was $746.40M, a 407.41% increase from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 3 month as first filed | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 6 month as first filed | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 9 month as first filed | Increase (Decrease) in Deferred Income Taxes 12 month | Increase (Decrease) in Deferred Income Taxes 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $194.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $290.40M 10-Q · filed 2026-07-30 | $522.90M derived: sum of 3 quarters · filed 2026-07-30 | $801.50M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $96.00M 10-Q · filed 2026-04-29 | $328.50M derived: sum of 2 quarters · filed 2026-04-29 | $607.10M derived: sum of 3 quarters · filed 2026-04-29 | $742.30M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $232.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $511.10M derived: sum of 2 quarters · filed 2026-02-04 | $646.30M derived: sum of 3 quarters · filed 2026-07-30 | $785.40M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $278.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $413.80M derived: sum of 2 quarters · filed 2026-07-30 | $552.90M 10-Q · filed 2025-10-28 | $833.10M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $135.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $274.30M 10-Q · filed 2026-07-30 | $554.50M derived: sum of 3 quarters · filed 2026-07-30 | $723.10M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $139.10M 10-Q · filed 2026-04-29 | $419.30M derived: sum of 2 quarters · filed 2026-04-29 | $587.90M derived: sum of 3 quarters · filed 2026-04-29 | $706.00M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $280.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $448.80M derived: sum of 2 quarters · filed 2026-02-04 | $566.90M derived: sum of 3 quarters · filed 2026-02-04 | $757.30M 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $168.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $286.70M derived: sum of 2 quarters · filed 2025-10-28 | $477.10M 10-Q · filed 2025-10-28 | $763.40M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $118.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $308.50M 10-Q · filed 2025-08-01 | $594.80M derived: sum of 3 quarters · filed 2026-02-04 | $720.50M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $190.40M 10-Q · filed 2025-04-29 | $476.70M derived: sum of 2 quarters · filed 2026-02-04 | $602.40M derived: sum of 3 quarters · filed 2026-02-04 | $811.70M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $286.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $412.00M derived: sum of 2 quarters · filed 2026-02-04 | $621.30M derived: sum of 3 quarters · filed 2026-02-04 | $837.80M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $125.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $335.00M derived: sum of 2 quarters · filed 2024-10-31 | $551.50M 10-Q · filed 2024-10-31 | $831.20M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $209.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $425.80M 10-Q · filed 2024-08-01 | $705.50M derived: sum of 3 quarters · filed 2025-02-05 | $791.20M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $216.50M 10-Q · filed 2024-05-02 | $496.20M derived: sum of 2 quarters · filed 2025-02-05 | $581.90M derived: sum of 3 quarters · filed 2025-02-05 | $737.90M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $279.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $365.40M derived: sum of 2 quarters · filed 2025-02-05 | $521.40M derived: sum of 3 quarters · filed 2025-02-05 | $746.40M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $85.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $241.70M derived: sum of 2 quarters · filed 2023-11-02 | $466.70M 10-Q · filed 2023-11-02 | $672.60M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $156.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $381.00M 10-Q · filed 2023-08-03 | $586.90M derived: sum of 3 quarters · filed 2024-02-05 | $579.90M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $225.00M 10-Q · filed 2023-05-04 | $430.90M derived: sum of 2 quarters · filed 2024-02-05 | $423.90M derived: sum of 3 quarters · filed 2024-02-05 | $382.20M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $205.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $198.90M derived: sum of 2 quarters · filed 2024-02-05 | $157.20M derived: sum of 3 quarters · filed 2024-02-05 | $147.10M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$48.70M derived: sum of 2 quarters · filed 2022-11-03 | -$58.80M 10-Q · filed 2022-11-03 | -$16.50M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | -$41.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$51.80M 10-Q · filed 2022-08-03 | -$9.50M derived: sum of 3 quarters · filed 2023-02-06 | -$9.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | -$10.10M 10-Q · filed 2022-05-04 | $32.20M derived: sum of 2 quarters · filed 2023-02-06 | $32.30M derived: sum of 3 quarters · filed 2023-02-06 | -$75.80M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $42.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $42.40M derived: sum of 2 quarters · filed 2023-02-06 | -$65.70M derived: sum of 3 quarters · filed 2023-02-06 | -$75.60M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$108.00M derived: sum of 2 quarters · filed 2021-11-04 | -$117.90M 10-Q · filed 2021-11-04 | -$97.30M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | -$108.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$118.00M 10-Q · filed 2021-08-05 | -$97.40M derived: sum of 3 quarters · filed 2022-02-07 | -$112.70M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | -$9.90M 10-Q · filed 2021-05-06 | $10.70M derived: sum of 2 quarters · filed 2022-02-07 | -$4.60M derived: sum of 3 quarters · filed 2022-02-07 | $110.00M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $20.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $5.30M derived: sum of 2 quarters · filed 2022-02-07 | $119.90M derived: sum of 3 quarters · filed 2022-02-07 | $130.60M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | -$15.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $99.30M derived: sum of 2 quarters · filed 2020-11-05 | $110.00M 10-Q · filed 2020-11-05 | $216.50M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $114.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $125.30M 10-Q · filed 2020-08-05 | $231.80M derived: sum of 3 quarters · filed 2021-02-08 | $249.80M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $10.70M 10-Q · filed 2020-05-05 | $117.20M derived: sum of 2 quarters · filed 2021-02-08 | $135.20M derived: sum of 3 quarters · filed 2021-02-08 | $144.30M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $106.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $124.50M derived: sum of 2 quarters · filed 2021-02-08 | $133.60M derived: sum of 3 quarters · filed 2021-02-08 | $140.00M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $27.10M derived: sum of 2 quarters · filed 2019-11-05 | $33.50M 10-Q · filed 2019-11-05 | $33.52M 10-Q · filed 2018-11-06 | -$393.54M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $15.50M 10-Q · filed 2019-08-06 | $15.49M 10-Q · filed 2018-08-02 | -$411.54M derived: sum of 3 quarters · filed 2020-02-07 | -$361.04M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $6.40M 10-Q · filed 2019-05-07 | $6.37M 10-Q · filed 2018-05-03 | -$420.64M derived: sum of 2 quarters · filed 2020-02-07 | -$370.14M derived: sum of 3 quarters · filed 2020-02-07 | -$353.39M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | -$427.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | -$376.54M derived: sum of 2 quarters · filed 2020-02-07 | -$359.79M derived: sum of 3 quarters · filed 2020-02-07 | -$318.80M 10-K · filed 2020-02-07 | -$318.81M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $50.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $67.25M derived: sum of 2 quarters · filed 2018-11-06 | $108.24M 10-Q · filed 2018-11-06 | $278.01M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $16.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $57.74M 10-Q · filed 2018-08-02 | $227.51M derived: sum of 3 quarters · filed 2019-02-07 | $255.19M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $40.99M 10-Q · filed 2018-05-03 | $210.76M derived: sum of 2 quarters · filed 2019-02-07 | $238.44M derived: sum of 3 quarters · filed 2019-02-07 | $321.30M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $169.77M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $197.45M derived: sum of 2 quarters · filed 2019-02-07 | $280.31M derived: sum of 3 quarters · filed 2019-02-07 | $360.10M 10-K · filed 2019-02-07 | $360.08M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $27.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $110.54M derived: sum of 2 quarters · filed 2017-11-08 | $190.33M 10-Q · filed 2017-11-08 | $245.97M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $82.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $162.65M 10-Q · filed 2017-08-03 | $218.30M derived: sum of 3 quarters · filed 2018-02-08 | $225.21M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $79.78M 10-Q · filed 2017-05-04 | $135.43M derived: sum of 2 quarters · filed 2018-02-08 | $142.34M derived: sum of 3 quarters · filed 2018-02-08 | $164.15M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $55.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $62.55M derived: sum of 2 quarters · filed 2018-02-08 | $84.37M derived: sum of 3 quarters · filed 2018-02-08 | $121.62M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $6.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $28.72M derived: sum of 2 quarters · filed 2016-11-04 | $65.97M 10-Q · filed 2016-11-04 | $85.09M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $21.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $59.07M 10-Q · filed 2016-08-04 | $78.18M derived: sum of 3 quarters · filed 2017-02-09 | $93.25M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $37.26M 10-Q · filed 2016-05-05 | $10.89M 10-Q · filed 2015-05-07 | $56.37M derived: sum of 2 quarters · filed 2017-02-09 | $71.44M derived: sum of 3 quarters · filed 2017-02-09 | $84.77M derived: sum of 4 quarters · filed 2017-02-09 | |||
| 2014-12-31 | $19.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $34.18M derived: sum of 2 quarters · filed 2017-02-09 | $47.52M derived: sum of 3 quarters · filed 2017-02-09 | $53.28M 10-K · filed 2017-02-09 | $66.60M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $15.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $28.40M derived: sum of 2 quarters · filed 2015-11-04 | $34.16M 10-Q · filed 2015-11-04 | |||||
| 2014-06-30 | $13.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $19.09M 10-Q · filed 2015-08-04 | ||||||
| 2014-03-31 | $5.76M 10-Q · filed 2015-05-07 | |||||||
| 2013-12-31 | -$62.20M 10-K · filed 2016-02-11 | -$63.60M 10-K · filed 2015-02-12 | ||||||
| 2012-12-31 | $340.16M 10-K · filed 2015-02-12 | $340.20M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |